On May 26, 2021 -Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, reported that investors to review the Company’s shareholder update conference call presentation via its website, which can be found here (Press release, Brooklyn ImmunoTherapeutics, MAY 26, 2021, View Source [SID1234580642]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights include:

A review of the company’s multiple programs, including its unique Phase 2 mixed cytokine asset, IRX-2, being developed for head and neck cancer
A discussion of its recently acquired license for mRNA cell reprogramming technology, mRNA-based gene editing, proprietary gene editing protein and proprietary lipid delivery system, which the company believes may provide a completely different approach to treating certain solid tumors, liquid tumors, sickle cell disease and a host of other inherited monogenic disorders that may have no currently available therapy
An overview of the company’s current financial position and future financial plans